| H01626 | |
| H number | H01626 |
| Name | Arteriosclerosis obliterans |
| Description | Arteriosclerosis obliterans (ASO) is one of the most common peripheral vascular diseases that causes ischemic symptoms of the lower limbs. Symptoms include discomfort, numbness, intermittent claudication, or even gangrene and ulceration. The risk factors of ASO include age, male gender, smoking, hypertension, hyperlipidemia, diabetes mellitus, chronic renal failure, and hyperhomocysteinemia. There are no definitive treatments for ASO. The efficacy of surgical treatment is not satisfactory, and medication is required to maintain the postoperative vascular patency. In order to relieve symptoms such as cold sensation and intermittent claudication, drug therapy such as antiplatelet therapy and vasodilatory drugs are useful in the treatment of some patients with ASO. Adsorption of low-density lipoprotein (LDL) has also been applied for the treatment of ASO. At present, the diagnosis of ASO depends on several clinical tests, such as angiography, estimations of ankle/brachial index (ABI), and pulse-wave velocity (PWV), as well as the measurement of circulating hs-CRP levels. However, these examinations can only be detectable when ASO already developed, and there was no predictable markers for ASO in its earlier stages. Recent studies have reported that some micro RNAs could be serum markers for early-stage ASO. |
| Category | Cardiovascular disease |
| Network | - |
| Gene | - |
| Pathogen | - |
| Env factor | - |
| Carcinogen | - |
| Drug | Isoxsuprine hydrochloride [DR:D01748] |
| Comment | - |
| Other DBs | ICD-11: BD40 ICD-10: I70 MeSH: D001162 |
| Reference | PMID:26632166 AUTHORS Horie T, Kimura T, Ono K TITLE Emerging Novel Biomarkers for Arteriosclerosis Obliterans. JOURNAL J Atheroscler Thromb 23:171-2 (2016) DOI:10.5551/jat.ED028 PMID:23364237 AUTHORS Ren S, Qian S, Wang W, Liu J, Liu P TITLE Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. JOURNAL Ann Thorac Cardiovasc Surg 19:30-4 (2013) DOI:10.5761/atcs.oa.12.02061 PMID:26370316 AUTHORS He XM, Zheng YQ, Liu SZ, Liu Y, He YZ, Zhou XY TITLE Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. JOURNAL J Atheroscler Thromb 23:196-206 (2016) DOI:10.5551/jat.30775 PMID:26272221 AUTHORS Mathur P, Ding Z, Saldeen T, Mehta JL TITLE Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease. JOURNAL Clin Cardiol 38:570-6 (2015) DOI:10.1002/clc.22422 PMID:23749750 AUTHORS Arai T TITLE Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. JOURNAL Adv Ther 30:528-40 (2013) DOI:10.1007/s12325-013-0030-7 PMID:22142554 AUTHORS Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G TITLE A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. JOURNAL Health Technol Assess 15:1-210 (2011) DOI:10.3310/hta15400 PMID:12886046 AUTHORS Nakamura T, Kawagoe Y, Matsuda T, Takahashi Y, Sekizuka K, Ebihara I, Koide H TITLE Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. JOURNAL Kidney Blood Press Res 26:185-91 (2003) DOI:10.1159/000071884 |